These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27323772)

  • 41. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
    Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
    Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Citrullinated peptide and its relevance to rheumatoid arthritis: an update.
    Luban S; Li ZG
    Int J Rheum Dis; 2010 Oct; 13(4):284-7. PubMed ID: 21199462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
    Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
    Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis.
    Lac P; Saunders S; Tutunea-Fatan E; Barra L; Bell DA; Cairns E
    J Autoimmun; 2018 May; 89():75-81. PubMed ID: 29242008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis.
    Hill JA; Al-Bishri J; Gladman DD; Cairns E; Bell DA
    J Rheumatol; 2006 Nov; 33(11):2115-9. PubMed ID: 16924693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile.
    Lundberg K; Bengtsson C; Kharlamova N; Reed E; Jiang X; Kallberg H; Pollak-Dorocic I; Israelsson L; Kessel C; Padyukov L; Holmdahl R; Alfredsson L; Klareskog L
    Ann Rheum Dis; 2013 May; 72(5):652-8. PubMed ID: 22661643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The fibrin-derived citrullinated peptide β60-74Cit₆₀,₇₂,₇₄ bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies.
    Cornillet M; Sebbag M; Verrouil E; Magyar A; Babos F; Ruyssen-Witrand A; Hudecz F; Cantagrel A; Serre G; Nogueira L
    Ann Rheum Dis; 2014 Jun; 73(6):1246-52. PubMed ID: 23636655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.
    Shi J; van de Stadt LA; Levarht EW; Huizinga TW; Toes RE; Trouw LA; van Schaardenburg D
    Arthritis Rheum; 2013 Apr; 65(4):911-5. PubMed ID: 23279976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
    Syversen SW; Goll GL; van der Heijde D; Landewé R; Lie BA; Odegård S; Uhlig T; Gaarder PI; Kvien TK
    Ann Rheum Dis; 2010 Feb; 69(2):345-51. PubMed ID: 19648126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
    Bang H; Egerer K; Gauliard A; Lüthke K; Rudolph PE; Fredenhagen G; Berg W; Feist E; Burmester GR
    Arthritis Rheum; 2007 Aug; 56(8):2503-11. PubMed ID: 17665451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis.
    Christensen AF; Lindegaard H; Hørslev-Petersen K; Hetland ML; Ejbjerg B; Stengaard-Pedersen K; Jacobsen S; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Tarp U; Pødenphant J; Østergaard M; Junker P
    J Rheumatol; 2011 Aug; 38(8):1563-8. PubMed ID: 21572145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
    El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
    J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis.
    Molad Y; Ofer-Shiber S; Pokroy-Shapira E; Oren S; Shay-Aharoni H; Babai I
    Eur J Clin Invest; 2015 Jun; 45(6):557-64. PubMed ID: 25832796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage.
    Brink M; Verheul MK; Rönnelid J; Berglin E; Holmdahl R; Toes RE; Klareskog L; Trouw LA; Rantapää-Dahlqvist S
    Arthritis Res Ther; 2015 Feb; 17(1):25. PubMed ID: 25889922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.
    Brink M; Hansson M; Mathsson L; Jakobsson PJ; Holmdahl R; Hallmans G; Stenlund H; Rönnelid J; Klareskog L; Rantapää-Dahlqvist S
    Arthritis Rheum; 2013 Apr; 65(4):899-910. PubMed ID: 23310951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.